Skip to main content

Table 1 Patient characteristics at the index date and mortality in the following 6 months

From: Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer

  Cases (%) Controls (%)
Number of patients 1,090 44,990
Mean age at index date ± SD 74.1 ± 5.7 71.1 ± 4.3
   Number of patients 66–74 670 (61.5) 36,900 (82.0)
   Number of patients 75–84 369 (33.9) 7,665 (17.0)
   Number of patients ≥ 85 51 (0.05) 425 (0.9)
Risk factors   
   Mammography in years 2 or 3 prior to the index date 514 (47.2) 35,229 (78.3)
   History of diagnostic and therapeutic breast procedures in the 3 prior to the index date 19 (1.7) 296 (0.7)
   Benign neoplasm of the breast in the 3 years prior to the index date 15 (1.4) 319 (0.7)
   Other breast disease in the 3 years prior to the index date 169 (15.5) 4,667 (10.4)
   Estrogen replacement therapy in the year prior to the index date 299 (27.4) 17,837 (39.7)
   Combined estrogen/progesterone therapy in the year prior to the index date 101 (9.3) 4,943 (11.0)
Visit to a gynecologist in the year prior to the index date 152 (13.9) 10,076 (22.4)
Exposure to the drugs of interest (one or more prescriptions in the year prior to the index date)   
   Ns-NSAID/COX-2 inhibitors 443 (40.6) 22,126 (49.2)
Ns-NSAIDs 102 (9.4) 5,572 (12.4)
COX-2 inhibitors 388 (35.8) 19,228 (42.7)
Rofecoxib 242 (22.2) 11,498 (25.6)
Celecoxib 203 (18.6) 10,269 (22.8)
   Aspirin 329 (30.2) 13,391 (29.8)
   Acetaminophen 253 (23.2) 10,159 (22.6)
   Not exposed* 375 (34.4) 12,260 (27.3)
  1. SD – standard deviation
  2. *Not exposed refers to the group of patients who were not exposed to ns-NSAIDs, aspirin, COX-2 inhibitors or acetaminophen during the year prior to the index date
\